Real-World Applications of Imipenem-Cilastatin-Relebactam: Insights From a Multicenter Observational Cohort Study
Open Forum Infectious Diseases · 27.03.2025 · 12 (4)
DOI: 10.1093/ofid/ofaf112 ↗Kurz gefasst
Klinische Studie in der Zeitschrift Open Forum Infectious Diseases, online erschienen am 26.02.2025. Verfasst von Kaylee E Caniff und 34 weiteren Autor:innen. Beteiligte Einrichtung: Anti-Infective Research Laboratory, Eugene Applebaum College of Pharmacy and Health Sciences, Wayne State University, Detroit, Michigan, USA. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIAID NIH HHS, Merck & Co.
Abstract (Originalsprache)
Background
Multidrug-resistant (MDR) gram-negative infections are a substantial threat to patients and public health. Imipenem-cilastatin-relebactam (IMI/REL) is a β-lactam/β-lactamase inhibitor with expanded activity against MDR Pseudomonas aeruginosa and carbapenem-resistant Enterobacterales. This study aims to describe the patient characteristics, prescribing patterns, and clinical outcomes associated with IMI/REL.
Methods
This was a retrospective, multicenter, observational study of patients ≥18 years old who received IMI/REL for ≥48 hours for a suspected or confirmed gram-negative infection. The primary outcome was clinical success, defined as improvement or resolution of infection-related signs or symptoms while receiving IMI/REL and the absence of 30-day microbiologic failure. Multivariable logistic regression analysis was performed to identify independent predictors of clinical success.
Results
The study included 151 patients from 24 US medical centers. IMI/REL was predominantly prescribed for lower respiratory tract infections, accounting for 52.3% of cases. Most patients were infected with a carbapenem-nonsusceptible pathogen (85.4%); P aeruginosa was frequently targeted (72.2%). Clinical success was achieved in 70.2% of patients. Heart failure, receipt of antibiotics within the past 90 days, intensive care unit admission at time of index culture collection, and isolation of difficult-to-treat resistant P aeruginosa were independently associated with a reduced odds of clinical success. Adverse events were reported in 6.0% of patients, leading to discontinuation of IMI/REL in 3 instances.
Conclusions
This study provides a comprehensive analysis of the real-world effectiveness and safety of IMI/REL. Comparative studies and investigations of specific subgroups will further enhance our understanding of IMI/REL in treating MDR infections.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Anti-Infective Research Laboratory, Eugene Applebaum College of Pharmacy and Health Sciences, Wayne State University, Detroit, Michigan, USA.
- Department of Clinical & Administrative Pharmacy Sciences, Howard University College of Pharmacy, Washington, DC, USA.
- Department of Pharmacy, Cleveland Clinic, Cleveland, Ohio, USA.
- Department of Pharmacy, The Ohio State University Wexler Medical Center, Columbus, Ohio, USA.
- Department of Pharmacy Practice and Translational Research, University of Houston College of Pharmacy, Houston, Texas, USA.
- Department of Pharmacy, Montefiore Medical Center, The Bronx, New York, USA.
ORCID-Profile: Kaylee E Caniff, Nicholas Rebold, Nikki Tran, Taryn A Eubank, Kevin W Garey, Katie E Barber, Tamara Krekel, Mark Biagi, Wesley D Kufel, Amy Carr, Jillian Hayes, Travis J Carlson, Jeremy Frens, Veena Venugopalan, Kristen Lucas, Ashlan J Kunz Coyne, James Sanders, Elisabeth Chandler, Rosanna Li, Julie Ann Justo, Russell Benefield, W Justin Moore, Jennifer Ross, Jenna Adams, Fritzie Albarillo, Sylvia Stefanos, Athena L V Hobbs, Nicholas Mercuro, Kristen Zeitler, Michael J Rybak
Förderung
- NIAID NIH HHS
- Merck & Co
Zitieren
APA
Caniff, K. E., Rebold, N., Xhemali, X., Tran, N., Eubank, T. A., Garey, K. W., Guo, Y., Chang, M., Barber, K. E., Krekel, T., Biagi, M., Kufel, W. D., Carr, A., Hayes, J., Carlson, T. J., Frens, J., Venugopalan, V., Lucas, K., Kunz Coyne, A. J., …, & Rybak, M. J. (2025). Real-World Applications of Imipenem-Cilastatin-Relebactam: Insights From a Multicenter Observational Cohort Study. Open Forum Infectious Diseases, 12(4). https://doi.org/10.1093/ofid/ofaf112
Vancouver
Caniff KE, Rebold N, Xhemali X, Tran N, Eubank TA, Garey KW, et al. Real-World Applications of Imipenem-Cilastatin-Relebactam: Insights From a Multicenter Observational Cohort Study. Open Forum Infectious Diseases. 2025;12(4). doi:10.1093/ofid/ofaf112
BibTeX
@article{Caniff2025,
author = {Caniff, Kaylee E and Rebold, Nicholas and Xhemali, Xhilda and Tran, Nikki and Eubank, Taryn A and Garey, Kevin W and Guo, Yi and Chang, Mei and Barber, Katie E and Krekel, Tamara and Biagi, Mark and Kufel, Wesley D and Carr, Amy and Hayes, Jillian and Carlson, Travis J and Frens, Jeremy and Venugopalan, Veena and Lucas, Kristen and Kunz Coyne, Ashlan J and Sanders, James and Chandler, Elisabeth and Li, Rosanna and Antosz, Kayla and Justo, Julie Ann and Benefield, Russell and Moore, W Justin and Ross, Jennifer and Adams, Jenna and Albarillo, Fritzie and Stefanos, Sylvia and Hobbs, Athena L V and Mercuro, Nicholas and Raux, Brian and Zeitler, Kristen and Rybak, Michael J},
title = {Real-World Applications of Imipenem-Cilastatin-Relebactam: Insights From a Multicenter Observational Cohort Study},
journal = {Open Forum Infectious Diseases},
year = {2025},
volume = {12},
number = {4},
doi = {10.1093/ofid/ofaf112}
}
EUVIMED